CTL-12

• Description:

  CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC50: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research[1].

• UNSPSC:

  12352005

• Target:

  Fatty Acid Synthase (FASN)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ctl-12.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=C2C(N=C(C3=C(O)C=CC(Cl)=C3)N2)=C1)N4CCN(C(C5(O)CC5)=O)CC4

• Molecular Formula:

  C22H21ClN4O4

• Molecular Weight:

  440.88

• References & Citations:

  [1]Singh S, et al. Design, synthesis, and anticancer activity of some novel 1H-benzo [d] imidazole-5-carboxamide derivatives as fatty acid synthase inhibitors[J]. Bioorganic Chemistry, 2023: 106658.. . .

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported